SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the second and final closing of its previously announced $25.0 million private placement of common stock. At the second closing held on August 8, 2007, VIA issued the remaining 8,402,940 shares of common stock for an aggregate purchase price of approximately $20.42 million. VIA had previously issued 1,885,125 shares of common stock for an aggregate purchase price of approximately $4.58 million in the first closing, which occurred on July 2, 2007. After fees and estimated offering expenses, VIA received aggregate net proceeds of approximately $23.2 million from the financing, which VIA intends to use to continue its research, development and commercialization activities.
